Stock BIO-TECHNE CORP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News BIO-TECHNE Corp Nasdaq

Equities

US8783771004

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for BIO-TECHNE Corp
06-11 Transcript : Bio-Techne Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 09:20 AM
06-06 Transcript : Bio-Techne Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 09:30 AM

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Transcript : Bio-Techne Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 09:20 AM
Transcript : Bio-Techne Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 09:30 AM
Transcript : Bio-Techne Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 09:20 AM
BIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES
AQ
BIO-TECHNE TO HIGHLIGHT MULTIPLE APPLICATIONS OF THE MAURICEFLEX SYSTEM AT THE ANNUAL ASMS CONFERENCE
AQ
BIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES
PR
BIO-TECHNE CORPORATION - SCALEREADY ANNOUNCES $20 MILLION G-REX GRANT PROGRAM FOR THE ADVANCEMENT OF CELL AND GENE THERAPY DEVELOPMENT AND MANUFACTURING
AQ
BIO-TECHNE TO HIGHLIGHT MULTIPLE APPLICATIONS OF THE MauriceFlex™ SYSTEM AT THE ANNUAL ASMS CONFERENCE
PR
Bio-Techne Corporation to Showcase Multiple Applications of the MauriceFlex?? System at the Annual ASMS Conference
CI
Transcript : Bio-Techne Corporation Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-29-2024 08:40 AM
ScaleReady Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (CGT) Development and Manufacturing
PR
BIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE
PR
BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY'S PROPRIETARY TECHNOLOGY
PR
Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration
CI
Citigroup Downgrades Bio-Techne to Neutral From Buy, With $85 Price Target
MT
Bio-techne Insider Sold Shares Worth $335,377, According to a Recent SEC Filing
MT
Transcript : Bio-Techne Corporation Presents at Bank of America Health Care Conference 2024, May-14-2024 02:20 PM
Ex-dividend day
FA
BIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTH CARE CONFERENCE 2024
PR
Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TECH Stock
  4. Stock
  5. News BIO-TECHNE Corp